Could a booster shot shield transplant patients from shingles?
NCT ID NCT07443709
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether an extra dose of the shingles vaccine (Shingrix) can boost immunity in people who have had a solid-organ transplant, like a kidney or liver. About 30% of transplant patients still get shingles after the standard two-dose vaccine, likely due to immune-suppressing medications. The trial will randomly assign 75 participants to receive either the booster or no booster, then measure antibody levels and track safety for one year.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Shingrix (recombinant zoster vaccine) booster dose
- What this could lead to
- If it works, this could lead to a simple booster shot that helps prevent shingles in transplant patients, reducing severe complications and hospital visits.
- What could go wrong
- This is a small, early-phase pilot study (75 people) and may not prove the booster is effective or safe for all transplant patients. Immune responses can vary, and there is a risk of side effects or organ rejection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 75 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Apr 2026
An estimate. Start dates often move.
- Expected to finish
-
Apr 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Aged ≥18 years * SOT recipient who has received two doses of the Shingrix® vaccine (primary vaccination). * At least 6 months after transplantation * At least 6 months after the completion of the Shingrix® primary vaccination series. * At least 8 weeks have elapsed since any treated episode of acute allograft rejection or At least 6 months if B-cell depleting antibodies (e.g. rituximab, alemtuzumab) was used as part of the treatment. * Signature of the written informed consent. Exclusion Criteria: * Acute febrile illness or active infection at the time of enrolment, as determined by the investigator (patients can be enrolled in a later stage). * Known hypersensitivity to any component of RZV. * Willing to become pregnant
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Zoster; herpes are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Lausanne University Hospital
Lausanne, Canton of Vaud, 1011, Switzerland